Guangzhou Hehe Pharmaceutical

Guangzhou Hehe Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company founded in 2022 and headquartered in Guangzhou's Huangpu District. The company operates as a comprehensive enterprise integrating the research, development, production, and sales of various drug formulations, including liquid injections, solid dosages, and soft capsules. Its therapeutic focus spans the digestive system, nervous system, oncology, and cardiovascular health. Guangzhou Hehe Pharmaceutical has successfully commercialized several products, including Calcium Chloride, Metoprolol, and Potassium Chloride injections, often through partnerships with contract manufacturing organizations. Despite being recognized as a High-tech Enterprise in 2024, the company faced significant regulatory challenges in early 2026, leading to the revocation of its national procurement qualifications.